Loading stock…

Option Care Health, Inc. (OPCH) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Option Care Health, Inc.

OPCHMarket cap $4.64BPrice $31.0

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Services

Delivers home-based infusion therapy and specialty pharmacy services to patients who'd otherwise need hospital visits. It's the largest independent provider in the US, treating conditions from infections to immune disorders — all through a nurse at your kitchen table.

In Bastion Portfolios?

52W Return+12%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+13%8

Revenue Forecast

Rev CAGR (1y)+2%3

Rev CAGR (3y)+5%4

Rev CAGR (5y)+7%6

Earnings Forecast

EPS Growth Y+1+50%9

EPS Growth Y+2+9%6

EPS Growth Y+3+10%6

Quality

Margins

EBIT Margin6%3

Net Income Margin4%3

Free Cash Flow Margin5%4

Debt

Net Debt/EBITDA2.44

Efficiency

ROE16%7

ROA6%7

Earnings Stability77

GEAR+AVERAGE44

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)165

P/E Ratio (Forward 3y)135

P/BV3.74

EV Multiples

EV/EBITDA Fwd125

EV/EBIT Fwd165

Yield

Free Cash Flow Yield6.5%8

Dividend Yieldna–

Momentum

Short term

1 month return+31%10

3 month return+44%10

YTD return-3%4

Mid term

Price vs 52wHigh84%6

1 year return+14%6

Long term

3 year return-5%3

5 year return+24%5

Risk Shield

Price Risk

Beta0.58

Volatility52%3

Free Cash Flow

Free Cash Flow Margin5%4

Free Cash Flow Yield6.5%8

Quality

ROCE13%7

Earnings Stability77

Net Debt/EBITDA2.44

02Growth

Is it actually growing, and how fast?

OPCHOption Care Health

Revenue FY25$5.6B

GROWTH RATING↗

AVERAGE46 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+13%8

Revenue, next 1Y+2%3

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+50%9

EPS growth, FY27E+9%6

EPS growth, FY28E+10%6

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 13%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 5%/yr).

WATCH

A mid-pack grower, ahead of 46% of companies worldwide.

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 13%/yr over the last 3 years; forecasts see it cooling to 5%/yr.

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG70 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+31%10

3-month return+44%10

YTD return-3%4

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return+14%6

3-year return-5%3

5-year return+24%5

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+31%) and over three months (+44%).

WATCH

Average long-term results. Multi-year returns are middling (-4.7% over three years and +24% over five), roughly average for the market.

It's up 14% over the past year, but 16% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level so far this year (-3%).

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Option Care. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

OPCHOption Care Health

Revenue FY25$5.6B

GROWTH RATING↗

AVERAGE46 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+13%8

Revenue, next 1Y+2%3

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+50%9

EPS growth, FY27E+9%6

EPS growth, FY28E+10%6

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 13%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 5%/yr).

WATCH

A mid-pack grower, ahead of 46% of companies worldwide.

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 13%/yr over the last 3 years; forecasts see it cooling to 5%/yr.

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG70 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+31%10

3-month return+44%10

YTD return-3%4

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return+14%6

3-year return-5%3

5-year return+24%5

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+31%) and over three months (+44%).

WATCH

Average long-term results. Multi-year returns are middling (-4.7% over three years and +24% over five), roughly average for the market.

It's up 14% over the past year, but 16% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level so far this year (-3%).

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Option Care. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community